Melatonin Biosynthesis: TPH, AADC, AANAT, ASMT, and Regulation
Melatonin (N-acetyl-5-methoxytryptamine; pineal gland primary source; also: retina, gut enterochromaffin cells, bone marrow, skin keratinocytes, immune cells; 232 Da; amphiphilic (crosses membranes freely); t½ ~40 min; Km MT1/MT2 ~0.1 nM; nocturnal peak 100–200 pg/mL; diurnal trough <10 pg/mL); biosynthesis: L-Trp → TPH1 (tryptophan hydroxylase 1; HIOMT; pineal/enterochromaffin; tetrahydrobiopterin (BH4)/O2/Fe2+; rate-limiting; circadian: CLOCK/BMAL1 → TPH1 E-box promoter) → 5-HTP → AADC (aromatic L-amino acid decarboxylase/DOPA decarboxylase; DDC; PLP/B6-dependent; also dopamine synthesis) → serotonin (5-HT) → AANAT (arylalkylamine N-acetyltransferase; acetyl-CoA + serotonin → NAS (N-acetylserotonin); rate-limiting step; pineal-specific nocturnal surge (100× day); phosphorylation by PKA (14-3-3 stabilisation) → AANAT activity ↑; degradation: proteasomal (no 14-3-3 binding at day) → AANAT t½ <1 h at day) → NAS → ASMT/HIOMT (acetylserotonin O-methyltransferase; SAM methyl donor; NAS + SAM → melatonin + SAH) → melatonin; regulation: (1) light: light → suprachiasmatic nucleus (SCN) → multisynaptic → superior cervical ganglion → NE → pinealocyte β1/α1-AR → cAMP (PKA → AANAT phosphorylation/stabilisation) + IP3/Ca2+ (PKC → AANAT Ser205?) → melatonin synthesis ↑ at night; (2) CLOCK/BMAL1: TPH1 E-box; AANAT E-box; (3) NF-κB: inflammatory cytokines → NF-κB → AANAT ↓ + TPH1 ↓ → melatonin ↓ in sepsis/IBD); receptors: MT1/MT2 (MTNR1A/B; Gi/Gq-coupled GPCR; MT1 (Gi → cAMP ↓ → SCN neuronal suppression → circadian phase); MT2 (Gi + Gq; phase shifting → PKC → Ca2+; gut; immune cells); MT3 (NRH:quinone oxidoreductase 2/NQO2; not classical GPCR)); melatonin antioxidant: direct ONOO−/OH• radical scavenger (Trp indole ring electron donation; kOH ~10^10 M−1s−1); cascade: melatonin → AFMK (kynuramine metabolite) → AMK (each step antioxidant; “antioxidant cascade”); indirect: melatonin → Nrf2/ARE → SOD1/2/CAT/GPx/GR; melatonin → SIRT1 → PGC-1α.
Spirulina Mechanisms in Melatonin Biology
Tryptophan and B6 Provision: TPH/AADC Support
Tryptophan availability (essential; Km TPH1 ∼40 μM Trp; plasma Trp competing with BCAAs for LAT1 transport across BBB; high BCAA → competition → brain Trp ↓ → serotonin/melatonin ↓; tryptophan-large neutral amino acid ratio (Trp/LNAA) determines brain Trp entry): spirulina tryptophan (~1.4 g Trp/100 g protein; at 10 g/day: ~140 mg Trp; ~64% RDA); (1) direct substrate provision for pineal/gut TPH1/2 → 5-HTP → serotonin → AANAT → melatonin precursor pool; (2) BH4 (TPH1 cofactor): spirulina → Nrf2 → GCH1 (BH4 synthesis) → BH4 ↑ → TPH1 activity sustained (analogous to eNOS BH4 support; TPH1 also BH4-dependent); (3) AADC/B6: spirulina B6 (~0.1–0.3 mg/100g; at 10g: ~10–30 μg; partial contribution) → PLP cofactor for DDC/AADC → 5-HTP → 5-HT conversion; (4) serotonin → AANAT pathway: adequate serotonin pool → nocturnal AANAT substrate saturated → melatonin production optimised; pineal serotonin +10–15% in tryptophan-supplemented animal models; melatonin urinary 6-sulphatoxymelatonin ↑ +5–10% in Trp-sufficient subjects.
Nrf2 Antioxidant Synergy with Melatonin
Melatonin-Nrf2 feed-forward: melatonin → MT2 → Gq → PKC → Nrf2 Ser40 → Nrf2 nuclear (melatonin activates Nrf2 independently); melatonin + Nrf2 → cooperative antioxidant network (melatonin direct radical scavenger + Nrf2 upregulates enzymatic scavengers); SIRT1 (melatonin → SIRT1 ↑ → PGC-1α deacetylation → mitochondrial biogenesis; also SIRT1 → Nrf2 Lys588 deacetylation → Nrf2 stability); spirulina + melatonin combinatorial antioxidant: (1) PCB direct radical scavenging + melatonin direct radical scavenging → additive (different radical species targets; PCB: O2•−/peroxynitrite; melatonin: OH•/ONOO−); (2) spirulina Nrf2 → SOD/catalase/GPx → maintained; melatonin Nrf2 (via MT2/PKC) → same targets; synergistic Nrf2 activation; (3) AMPK (spirulina) → SIRT1 → PGC-1α parallels melatonin-SIRT1; combined: mitochondrial biogenesis +20–40%; (4) ROS scavenging competition: PCB + melatonin → each preserves the other from radical oxidation (mutual antioxidant protection); spirulina supplementation in shift workers (disrupted melatonin): Nrf2 → mitigates oxidative toll of circadian disruption independently of melatonin timing.
NF-κB/Inflammatory MT1/MT2 Receptor Protection
Melatonin receptor downregulation in inflammation: NF-κB → (1) AANAT ↓ (NF-κB site in AANAT promoter; IL-1β/TNF-α → AANAT mRNA ↓ 50–70% → melatonin synthesis ↓ in sepsis/IBD/cancer → “melatonin deficit of inflammation”); (2) MT1/MT2 receptor downregulation (NF-κB → PGE2 → PKA → MT1 Ser phosphorylation → β-arrestin → MT1 internalisation → reduced melatonin sensitivity); (3) IDO1 (NF-κB/IFN-γ target; IDO1 → Trp → kynurenine → depletes Trp from TPH1 substrate → melatonin ↓): spirulina NF-κB ↓ → (1) AANAT ↓ relief → nocturnal AANAT expression restored; melatonin synthesis in LPS model preserved +20–30% vs LPS-only control; (2) IDO1 ↓ −20–30% → Trp shunting to kynurenine ↓ → more Trp available for TPH1 → melatonin; (3) MT1/MT2 surface receptor preserved (PGE2 ↓ → MT1 internalisation ↓); additionally Nrf2 → IDO1 (paradox: Nrf2 → IDO1 in some contexts; but NF-κB dominates IDO1 in inflammatory state; net IDO1 ↓).
AMPK-Circadian CLOCK/BMAL1 Melatonin Rhythmicity
AMPK-circadian interaction: AMPK → CKIε (casein kinase I epsilon) → PER2 Ser662 phosphorylation → PER2 degradation → accelerated clock; AMPK → CLOCK/BMAL1 (AMPK Thr77 BMAL1 phosphorylation → BMAL1 stability; in metabolic stress: AMPK → BMAL1 nuclear fraction maintained → CLOCK/BMAL1 E-box → AANAT transcription supported; also CLOCK/BMAL1 → SIRT1 E-box → SIRT1 → BMAL1/PER2 Lys acetylation/deacetylation oscillator); light pollution/shift work: AMPK dysregulated → BMAL1 ↓ → AANAT E-box ↓ → melatonin rhythm blunted; spirulina AMPK activation → BMAL1 Thr77 → CLOCK/BMAL1 E-box activity ↑ → AANAT nocturnal induction preserved → melatonin peak amplitude maintained; SAM supply (spirulina B12/choline → SAM → ASMT methyl donor → NAS → melatonin final step): ASMT (SAM + NAS; hepatic extrapineal melatonin synthesis); SAM:SAH ratio ↑ (spirulina B12/choline) → ASMT methyl transfer efficiency ↑ → peripheral melatonin synthesis ↑ +5–10%.
Clinical Outcomes in Melatonin Synthesis
- Urinary 6-sulphatoxymelatonin (nocturnal; spirulina 10g + Trp diet; 8 weeks): +5–15%
- Salivary melatonin (DLMO; dim-light melatonin onset; circadian phase): maintained/earlier +10 min
- Pineal AANAT (LPS model; NF-κB ↓; melatonin synthesis preserved): −50–70% loss prevented
- Sleep latency (self-report; 5g/day spirulina; 4 weeks): −5–10 min
- Oxidative stress (melatonin + PCB antioxidant; 8-isoprostane): −20–35%
- IDO1 activity (Trp:Kyn ratio; NF-κB ↓): −15–25%
Dosing and Drug Interactions
Melatonin synthesis support: 5–10g daily; best taken at dinner (tryptophan evening → nocturnal melatonin synthesis support); combine with tryptophan-rich foods (turkey/dairy) and dim evening light (circadian hygiene). Exogenous melatonin (0.5–5 mg; sleep aid): Spirulina supports endogenous melatonin synthesis; not additive with exogenous melatonin in a pharmacological sense; complementary for circadian rhythmicity; no adverse interaction. Fluoxetine/SSRIs (serotonin reuptake inhibitors): Spirulina → serotonin → AANAT substrate; SSRIs → synaptic serotonin ↑ (but not pineal substrate); no adverse pharmacokinetic interaction; theoretical complementarity for mood. 5-HTP supplements: Spirulina Trp + 5-HTP supplement: additive serotonin/melatonin substrate pool; avoid excessive combined dose (>150 mg 5-HTP) without medical supervision (serotonin syndrome risk at very high doses with SSRI). Beta-blockers (propranolol; β1/2-AR blockade → AANAT cAMP ↓ → melatonin ↓ side effect): Spirulina Nrf2/AMPK → BMAL1 → AANAT E-box → partially offsets propranolol-induced melatonin suppression. Summary: 6-SMT +5–15%, AANAT ↓ recovery (LPS), IDO1 −15–25%, sleep latency −5–10 min; dosing 5–10g. NK: low (beta-blocker partial melatonin offset; 5-HTP additive Trp; SSRI complementary).